⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for apixaban 2.5 mg oral tablet [eliquis]

Every month we try and update this database with for apixaban 2.5 mg oral tablet [eliquis] cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsNCT04243122
Myeloproliferat...
Essential Throm...
JAK2 Mutation
Polycythemia Ve...
Primary Myelofi...
Venous Thromboe...
Apixaban 2.5 MG...
Aspirin 81 mg
18 Years - Ottawa Hospital Research Institute
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsNCT04243122
Myeloproliferat...
Essential Throm...
JAK2 Mutation
Polycythemia Ve...
Primary Myelofi...
Venous Thromboe...
Apixaban 2.5 MG...
Aspirin 81 mg
18 Years - Ottawa Hospital Research Institute
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsNCT04243122
Myeloproliferat...
Essential Throm...
JAK2 Mutation
Polycythemia Ve...
Primary Myelofi...
Venous Thromboe...
Apixaban 2.5 MG...
Aspirin 81 mg
18 Years - Ottawa Hospital Research Institute
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: